Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in atherosclerosis with T2DM or IGT
NCT00995930Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of canakinumab in atherosclerosis, sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00995930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995930.